ozanimod rpc1063 is an oral selective modulator of the sphingosine 1 phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease the effects of high fat and low fat meals on the pharmacokinetics pk of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized open label crossover trial each subject received a 1 mg dose of ozanimod hydrochloride under 3 meal conditions fasted high fat and low fat each separated by 7 days mean plasma concentration time profiles for ozanimod and its active metabolites rp101988 major rp101075 minor were similar under all 3 conditions moreover all pk parameters for ozanimod rp101988 and rp101075 were similar under the 3 meal conditions the 90 confidence intervals cis for the ratios of geometric least squares mean fed fasted were within the equivalence limits of 0 80 to 1 25 for area under the concentration time curve from time 0 to infinity auc and maximum plasma concentration c for ozanimod rp101988 and rp101075 except for the high fat effect on rp101075 c 90 ci 0 76 0 88 given this lack of a food effect on the exposure of ozanimod and its active metabolites ozanimod can be taken without regard to meals.